Eagle Fund SP1 Overview
- Investor Type
-
Venture Capital
- Status
-
Active
- Investments
-
3
- Portfolio
-
1
- Exits
-
1
Eagle Fund SP1 General Information
Company Description
Eagle Fund SP1 is a venture capital firm based in Tokyo, Japan. The firm seeks to invest in biopharmaceutical companies.
Business Details
Investor Status
Primary Investor Type
Corporate Office
- 49th Floor, Shinjuku Mitsui Building
- 2-1-1 Nishi-Shinjuku
- Tokyo
- Japan
Eagle Fund SP1 Investments (3)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Company Stage | Lead Partner |
|---|---|---|---|---|---|---|
| DiscGenics | 04-Dec-2020 | Later Stage VC | Drug Discovery | Clinical Trials - General | ||
| Innovacell | 01-Jan-2019 | Drug Discovery | Generating Revenue | |||
| Innovacell | 18-Feb-2012 | Drug Discovery | Generating Revenue |
Eagle Fund SP1 Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size |
|---|---|---|---|
| Innovacell | 24-Feb-2026 |
Eagle Fund SP1 Investments by Industry, Year, and Region
Eagle Fund SP1 FAQs
-
What is Eagle Fund SP1?
Eagle Fund SP1 is a venture capital firm based in Tokyo, Japan.
-
Where is Eagle Fund SP1 headquartered?
Eagle Fund SP1 is headquartered in Tokyo, Japan.
-
How many investments has Eagle Fund SP1 made?
Eagle Fund SP1 has made 3 investments.
-
What has Eagle Fund SP1 invested in?
Eagle Fund SP1 has made numerous investments in companies like DiscGenics and Innovacell within the Drug Discovery industry.
-
What has Eagle Fund SP1 invested in recently?
Eagle Fund SP1's latest investment was on 04-Dec-2020 in DiscGenics, a company within the Drug Discovery industry.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process